Skip to main content
Inventiva logo

Inventiva — Investor Relations & Filings

Ticker · IVA ISIN · FR0013233012 LEI · 969500I9Y690B3FZW590 PA Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2021-10-08 Major Shareholding Noti…
Country FR France
Listing PA IVA

About Inventiva

https://inventivapharma.com/

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrotic diseases, lysosomal storage disorders, and oncology. Its lead product candidate, lanifibranor, is a pan-PPAR (peroxisome proliferator-activated receptor) agonist being evaluated in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). Lanifibranor is designed to address the key features of NASH, including steatosis, inflammation, ballooning, and fibrosis. The candidate has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) based on positive Phase IIb results.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissements de seuils (article L. 233-7 du code de commerce)" which translates to "Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)". This type of filing in France (AMF regulated) specifically reports changes in significant share ownership or voting rights by directors or major shareholders, often resulting from transactions or capital changes. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers notification of changes in significant share ownership levels crossing thresholds. The content details the percentage of capital and voting rights held by M. Frédéric Cren and M. Pierre Broqua after crossing specific thresholds (20%, 15%, 10%).
2021-10-08 French
Inventiva annonce sa participation à plusieurs conférences investisseurs en octobre 2021
Regulatory Filings Classification · 99% confidence The document is a press release from Inventiva dated September 28, 2021, announcing the management team's participation in three investor conferences scheduled for October 2021. The content details the names, dates, and formats of these upcoming events ('HealthTech Innovation Days 2021', 'Portzamparc Health Biotech Seminar', 'H.C. Wainwright 23rd Annual Global Investment Conference'). This type of announcement, informing investors about management's schedule for meeting with investors and presenting company updates at industry events, aligns best with the Investor Presentation (IP) category if it were a presentation itself, or more accurately, an announcement about future investor engagement. Since the document is an announcement about participation in investor conferences, it is classified as an Investor Presentation (IP) announcement or related communication. Given the options, 'IP' (Investor Presentation) is the closest fit for material related to management engaging with investors at conferences, although 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) could also be considered if it were purely a notice. However, because it details specific investor-facing events where presentations are likely to occur, 'IP' is the most contextually relevant classification for this type of forward-looking investor relations material.
2021-09-28 French
Inventiva announces participation at several investor conferences in October 2021
Regulatory Filings Classification · 98% confidence The document is a press release dated September 28, 2021, announcing that the company's leadership will participate in three upcoming investor conferences in October 2021. It details the names, dates, and formats of these events (HealthTech Innovation Days, Portzamparc Health Biotech Seminar, H.C. Wainwright Conference). This type of announcement, which informs investors about management's schedule for meetings and presentations at industry events, is best classified as an Investor Presentation (IP) related activity announcement, or more generally, a communication aimed at investors regarding corporate outreach. Since there is no specific category for 'Investor Conference Schedule Announcement,' and it is not a formal regulatory filing like 10-K or ER, the closest fit among the provided options that relates to investor engagement and corporate updates outside of formal financial reporting is often grouped with Investor Presentations (IP) or sometimes treated as a general Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the content is purely about scheduling investor meetings/presentations, it strongly aligns with the context of investor relations activities. Since it is not the presentation itself, but an announcement *about* participation, and it is not a short notice about a report publication (RPA), I will classify it as an Investor Presentation (IP) as it directly relates to investor engagement activities, or RNS as a general announcement. Given the context of financial reporting databases, announcements about management's schedule for investor engagement are often categorized under IP or RNS. I will choose RNS as the most appropriate general regulatory/corporate announcement category when a specific 'Investor Outreach Schedule' code is missing, as it is a general corporate update.
2021-09-28 English
Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the completion of a capital raise (sale of ADSs) through an 'At-the-Market' (ATM) program. It details the number of shares issued, the price per share, the impact on share capital, and the regulatory context of the transaction. This falls under the category of capital and financing updates, as it describes a specific financing activity rather than a general regulatory filing or a periodic report.
2021-09-23 English
Inventiva lève 30 millions de dollars dans le cadre de son programme At-The-Market pour des investisseurs institutionnels spécialisés existants et nouveaux
Capital/Financing Update Classification · 98% confidence The document is a press release dated September 23, 2021, announcing that Inventiva has raised $30 million through its At-The-Market (ATM) program by issuing new American Depositary Shares (ADSs). This action directly relates to the company's fundraising and capital structure activities. This fits the definition of 'Capital/Financing Update' (CAP). Although it mentions SEC filings (Form F-3), the primary content is the announcement of the capital raise itself, not the filing document, nor is it a general regulatory announcement (RNS) or a report publication announcement (RPA) as it details the transaction results.
2021-09-23 French
Inventiva annonce la décision de la FDA que le statut « Fast Track » accordé à lanifibranor dans la NASH englobe le traitement de la NASH avec cirrhose compensée
Regulatory Filings Classification · 95% confidence The document is a press release dated September 21, 2021, announcing a regulatory decision from the US FDA regarding the 'Fast Track' status for the drug lanifibranor concerning NASH with compensated cirrhosis. The text details a specific regulatory event, provides commentary from management, and includes standard boilerplate information about the company (Inventiva) and forward-looking statements. This type of announcement, focusing on a specific regulatory milestone or clinical update, is characteristic of an Earnings Release (ER) if it were summarizing period results, but here it is a specific, non-periodic announcement about regulatory progress. It is not a full Annual Report (10-K), an Audit Report (AR), a Call Transcript (CT), or a Dividend Notice (DIV). Since it is a formal announcement of a significant corporate/regulatory event that is not covered by the more specific categories like M&A (TAR) or Capital Change (CAP), it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for specific regulatory news releases that aren't financial results summaries (ER) or proxy materials (DEF 14A/PSI). Given the nature of the announcement (FDA decision), it is a regulatory communication, but since RNS is the general regulatory announcement category, it is the most appropriate fit among the choices for a press release detailing a regulatory status update.
2021-09-21 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.